Proteomic classification of breast cancer

Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon B. Mills, Bryan Hennessy

    Research output: Contribution to journalArticle

    15 Scopus citations

    Abstract

    Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

    Original languageEnglish (US)
    Pages (from-to)1495-1509
    Number of pages15
    JournalCurrent Drug Targets
    Volume13
    Issue number12
    DOIs
    StatePublished - Dec 3 2012

    Keywords

    • Breast cancer
    • Molecular technology
    • Proteome
    • RPPA

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmacology
    • Drug Discovery
    • Clinical Biochemistry

    Fingerprint Dive into the research topics of 'Proteomic classification of breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Kamel, D., Brady, B., Tabchy, A., Mills, G. B., & Hennessy, B. (2012). Proteomic classification of breast cancer. Current Drug Targets, 13(12), 1495-1509. https://doi.org/10.2174/138945012803530080